2nd Quarter - Report

SUMITOMO PHARMA AMERICA, INC.(FORMERLY SUNOVION PHARMACEUTICALS INC.) for SUMITOMO PHARMA AMERICA, INC. (FORMERLY SUNOVION PHARMACEUTICALS INC.)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$280,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2013 $280,000 Replaced
2nd Quarter - Amendment Jul 26, 2013 $290,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Discussions regarding patent reform

LobbyistCovered position, as disclosed
ENGEL BURNS —
ANTHONY MAGNETTI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Discussions related to the IPAB Issues regarding general health care reform (no specific bill#) Essential Health Benefits Discussions regarding Perscription Drug User Fee Act (PDUFA) Reauthorization

LobbyistCovered position, as disclosed
ENGEL BURNS —
ANTHONY MAGNETTI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Issues regarding Medicare Part D, Medicare reimbursement issues Discussions regarding Medicare Part B

LobbyistCovered position, as disclosed
ENGEL BURNS —
ANTHONY MAGNETTI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.